abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Hepatitis B · Mixed Dyslipidemia · ARWR
Arrowhead Pharmaceuticals Ireland
Arrowhead Pharmaceuticals Ireland Limited
Arrowhead Pharmaceuticals Ireland drug portfolio — 34 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US HQ
746 Employees
Public company Type
ARWR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 177 E Colorado Blvd, Suite 700, Pasadena, California 91105, US
- Employees
- 746
- Programs
- 63
- Drugs
- 34
- Patents
- 126
Arrowhead Pharmaceuticals Ireland pipeline
Portfolio lens on 34 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Arrowhead Pharmaceuticals Ireland drug portfolio — 34 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA polymerase catalytic subunit.
- Target
- DNA polymerase catalytic subunit
- Mechanism
- Human herpesvirus 1 DNA polymerase inhibitor
-
US regulatory status: approved.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Arrowhead Pharmaceuticals Ireland's portfolio.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Arrowhead Pharmaceuticals Ireland's portfolio. Molecular target: Surface antigen (HBsAg).
- Target
- Surface antigen (HBsAg)
- Mechanism
- Surface antigen (HBsAg) vaccine antigen
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
plozasiran
Cardiovascular system (C10)Cardiovascular system (C10) compound in Arrowhead Pharmaceuticals Ireland's portfolio.
-
US regulatory status: approved.
-
ranolazine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Plasminogen inhibitor
-
Development asset linked to Arrowhead Pharmaceuticals Ireland in public FDA and regional records.
-
ulipristal acetate
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor modulator